جست‌وجوی استاد و پژوهشگر

Zeyad Ibrahimمشاهده پروفایل

پژوهشگر

• Pharmacogenomics
• Cancer Treatment
• Pediatric Oncology
• +۳ مورد دیگر

Zeyad Ibrahim is a Doctor of Philosophy student at the University of Western Australia, engaged in Casual Teaching and acting as a Multi-Discipline Contractor/Visitor. Affiliated with the School of Allied Health, UWA Medical School, and the UWA Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research), he focuses on pharmacogenomics in pediatric cancer treatment. Education: Doctor of Philosophy, School of Allied Health, University of Western Australia. Research interests include methotrexate pharmacogenomics, CRISPR/Cas9 genomic models for drug efficacy assessment, and systematic reviews addressing gaps in pediatric cancer therapies. His work aligns with UN Sustainable Development Goals related to health and well-being. Publications include two peer-reviewed abstracts in the Asia-Pacific Journal of Clinical Oncology (2019), exploring methotrexate pharmacogenomics in pediatric cancers and a CRISPR-based genomic model. He received the Churchill Fellowship 2022 for pharmacogenomics research. Grants: Co-investigator on two major projects funded by the Western Australian Department of Health, focusing on personalized cancer treatment using pharmacogenomics to improve outcomes and reduce costs for seriously ill children (MiSSK initiative). Labs/Teams: Involved with the Centre for Optimisation of Medicines and collaborates with the Harry Perkins Institute of Medical Research.

Adam C Steinمشاهده پروفایل

دانشیار

• Gastroenterology
• Hepatology
• Inflammatory Bowel Disease
• +۵ مورد دیگر

Adam C Stein is an Associate Professor in the Department of Medicine at Northwestern University's Feinberg School of Medicine, specializing in gastrointestinal disorders of the small bowel. He provides clinical care at Northwestern Memorial Hospital and Ann & Robert H. Lurie Children's Hospital of Chicago, with expertise in Crohn's disease, celiac disease, intestinal failure, and malnutrition management. Education: MD from University of Illinois, Chicago (2007) Residency in Internal Medicine at University of Chicago (2010) Fellowship in Gastroenterology at University of Chicago (2013) Fellowship in Nutrition at University of Chicago (2014) Dr. Stein's research focuses on small bowel pathologies including obscure gastrointestinal bleeding, cystic fibrosis-related GI complications, and advanced endoscopic techniques like video capsule endoscopy and double balloon enteroscopy. His clinical work emphasizes nutritional support through parenteral nutrition and tube feeding for complex malabsorption syndromes. Recent publications (2022-2024) demonstrate concentrated research on gastrointestinal manifestations in rare diseases (nephropathic cystinosis) and cystic fibrosis, with particular attention to nutritional management barriers and drug safety profiles in inflammatory bowel disease therapies. No scientific awards are listed in the current profile. Information regarding student advising and research grants is not specified in available materials, though Dr. Stein maintains active industry collaborations through consulting roles with AbbVie, Amgen, and Takeda Pharmaceuticals. As a member of the Division of Gastroenterology and Hepatology, Dr. Stein collaborates with multidisciplinary teams across Northwestern Medicine's academic hospitals, contributing to clinical committees including the ACG Training Committee (2017-2023) and editorial boards such as Current Gastroenterology Reports (2019-2023).

Francesca Rodinoمشاهده پروفایل

پژوهشگر ارشد

• Electrochemical Biosensors
• Therapeutic Drug Monitoring
• Precision Oncology
• +۴ مورد دیگر

Francesca Rodino is a Doctoral Assistant and Research Fellow at École Polytechnique Fédérale de Lausanne (EPFL), affiliated with the School of Engineering and the Electrical and Microengineering Institute (IEM). She conducts research at the BCI Lab in Neuchâtel, focusing on electrochemical biosensors and precision oncology platforms. She is concurrently pursuing a PhD in Microsystems and Microelectronics (EDMI program) at EPFL. Education: B.Sc. in Biomedical Engineering, Politecnico di Torino (2019) M.Sc. in Biomedical Instrumentation, Politecnico di Torino (2022) Research Focus: Her work integrates electrochemical sensors, machine learning, and microsystems for therapeutic drug monitoring and biomedical diagnostics. Key areas include: (1) Multi-drug quantification using intelligent sensors for personalized cancer therapy, (2) Machine learning-driven optimization of electrochemical detection, (3) Microfluidic platforms for disease diagnosis (e.g., malaria), and (4) Wearable systems for neural prosthetics. Her research bridges biomedical engineering, electronics, and data science to advance precision medicine. Publication Trends: Recent articles (2022-2024) demonstrate strong emphasis on electrochemical sensors enhanced by machine learning for pharmaceutical monitoring, particularly in oncology. Secondary themes include microfluidic diagnostics, wearable medical devices, and environmental sensors. Over 85% of publications involve interdisciplinary collaborations, reflecting integration of engineering, computational methods, and clinical applications. Teaching & Leadership: Teaching Assistant for Bio-nano-chip design (EE-517) and MEMS practicals II (MICRO-503) EPFL team coach for international SensUs biotechnology competition

• Pharmacogenetics
• Clinical Pharmacology
• Personalized Medicine
• +۴ مورد دیگر

Dr. Vera Deneer is an Associate Professor of Clinical Pharmacology at the Utrecht Institute for Pharmaceutical Research (UIPS) within the Faculty of Science at Utrecht University, specializing in the Division of Pharmacoepidemiology and Clinical Pharmacology since 2019. She also serves as a hospital pharmacist and clinical pharmacologist at the University Medical Center Utrecht (UMC Utrecht) at the Department of Clinical Pharmacy since 2017. Dr. Deneer holds significant leadership positions including Vice-Chair of the Medicines Evaluation Board (MEB-CBG) since 2019 and Chair of the Dutch Pharmacogenetics Working Group (DPWG). Dr. Deneer received her PharmD from Utrecht University in 1991 and her PhD from Groningen University in 2003, with research focused on clinical pharmacology and pharmacokinetics of antiarrhythmic drugs in atrial fibrillation. She completed clinical training in hospital pharmacy in 1994 and clinical pharmacology training in 1998. Prior to her current positions, she served as Head of the Pharmacogenetics, Pharmaceutical and Toxicological Laboratory at St. Antonius Hospital, Nieuwegein/Utrecht from 1998 to 2017. Her research focuses on personalized medicine through the study of biomarkers including genetic variants, patient characteristics, and clinical parameters to optimize drug treatment efficacy and safety. Her work primarily targets cardiovascular disease, lung cancer, and immune-mediated inflammatory diseases. She also investigates clinical reasoning and decision-making by pharmacists to improve medication management in clinical practice. Dr. Deneer serves as principal investigator for multiple research projects funded by The Netherlands Organisation for Health Research and Development. Dr. Deneer's recent publications demonstrate her leadership in pharmacogenetics guidelines development, with numerous Dutch Pharmacogenetics Working Group (DPWG) guidelines published in 2023-2025 covering gene-drug interactions for various medication classes including antidepressants, antipsychotics, anti-epileptics, and cardiovascular medications. Her work spans both clinical implementation research and educational aspects of pharmacy practice. Among her significant appointments, Dr. Deneer serves as Vice-Chair of the Medicines Evaluation Board (MEB-CBG) and Chair of the Dutch Pharmacogenetics Working Group (DPWG). She previously chaired a medical research ethics committee from 2012-2017 and serves on multiple national and hospital committees related to pharmacotherapy and drug safety. Dr. Deneer has been actively involved in mentoring pharmacy students and professionals, with recent publications focusing on clinical decision-making education for pharmacists. Her work bridges the gap between pharmacogenetic research and clinical implementation, with particular emphasis on optimizing drug treatment strategies for individual patients while minimizing adverse drug reactions.

Charlotte Kloftمشاهده پروفایل

استاد

• Pharmacometrics
• Computational Disease Modeling
• Therapeutic Drug Monitoring
• +۶ مورد دیگر

Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.

• Tumor Glycocalyx Targeting
• Protease-Activated Anticancer Prodrugs
• Cancer Drug Development
• +۴ مورد دیگر

Robert Falconer serves as Professor of Medicinal Chemistry and Director of the Institute of Cancer Therapeutics (ICT) at the University of Bradford. A registered pharmacist with the General Pharmaceutical Council, he leads a multidisciplinary research team focused on tumor glycocalyx targeting and protease-activated anticancer prodrugs. His academic journey spans from pharmacy training at The School of Pharmacy, University of London to establishing the medicinal chemistry program at ICT in 2005. Pharmacy Degree: The School of Pharmacy, University of London (now UCL School of Pharmacy) PhD in Medicinal Chemistry: London (2000) Professional Registration: General Pharmaceutical Council Professor Falconer's research centers on tumor glycocalyx modulation through polysialyltransferase inhibition and protease-activated drug delivery systems. His work spans osteosarcoma, neuroblastoma, breast, and prostate cancers with emphasis on developing targeted therapies that minimize systemic toxicity. The Falconer group employs computational design, solid-phase synthesis, and advanced biological evaluation techniques to develop novel anticancer agents. His publication portfolio demonstrates consistent focus on tumor-specific activation mechanisms (2023-2025), glycocalyx-targeted metastasis inhibition (2019-2021), and prodrug development (2010-2014). Recent work emphasizes theranostic applications and DNA repair targeting for pediatric cancers. Fellow of the Royal Society of Chemistry Former Honorary Treasurer, RSC Central Yorkshire Local Section Trust (2012-2018) Registered Pharmacist with General Pharmaceutical Council As principal investigator, Falconer has secured substantial funding from Breast Cancer Now, Bone Cancer Research Trust, Worldwide Cancer Research, and Neuroblastoma UK. He leads the £2m ICT Doctoral Training Centre and co-founded spin-out company Incanthera plc, which is advancing the MMP-targeted prodrug ICT2588 to clinical trials. His mentorship includes three PhD students and multiple postdoctoral researchers developing next-generation cancer therapeutics. The Falconer group operates within the ICT's state-of-the-art facilities, collaborating with Stanford University, University of Sheffield, and Ellipses Pharma. Current projects address unmet needs in pediatric oncology while developing platform technologies applicable across multiple cancer types.

• Surface Chemistry
• Plasmonic Materials
• Surface Plasmon Resonance
• +۷ مورد دیگر

Jean-François Masson is a Full Professor in the Department of Chemistry at the Faculty of Arts and Sciences, Université de Montréal. He directs research in instrumentation, surface chemistry, and plasmonic materials, developing innovative biosensors for medical diagnostics and analysis. His work bridges analytical chemistry, nanotechnology, and artificial intelligence to create portable diagnostic devices. Position: Full Professor, Department of Chemistry Institution: Université de Montréal Research Focus: Plasmonic biosensors, surface chemistry, medical diagnostics Contact: jf.masson@umontreal.ca | 514 343-7342 Masson earned his BSc in Chemistry from Université de Sherbrooke in 2001, followed by a PhD in Analytical Chemistry from Arizona State University in 2005. He completed postdoctoral training at Georgia Tech before joining Université de Montréal's Chemistry Department in 2007. His research focuses on developing spectroscopic instruments for biomolecule analysis in medical samples through biosensors. He studies nano- and microstructure properties to enhance instrument sensitivity and surface chemistries to improve analysis selectivity in biological fluids. His plasmonic technology uses surface plasmon resonance at the intersection of analytical chemistry, nanotechnology, and artificial intelligence, employing gold thin films on chips that change color to detect the presence of antibodies like those for COVID-19. His publication trends show a consistent focus on surface plasmon resonance applications, with increasing emphasis on portable diagnostic devices, clinical applications, and integration with artificial intelligence. His work spans fundamental plasmonic material science to practical medical diagnostics, particularly in chemotherapy monitoring and infectious disease detection. 7 patents filed or granted for innovations in instrumentation, surface chemistry, and plasmonic materials License granted to Rose Street Labs (2005) Numerous research grants from NSERC, FRQNT, CIHR, and other major funding agencies Professor Masson has supervised over 20 graduate students (PhD and MSc) since joining Université de Montréal. His research has attracted significant funding, including multiple NSERC Discovery Grants, FRQNT team projects, and collaborations with hospitals for clinical validation of his diagnostic technologies. He leads several major research initiatives including projects on plasmonic optophysiology, chemical biology of sugars, and portable sensors for inflammation markers. His research is conducted through multiple units including the Thin Film Physics and Technology Research Group (GCM), the Neural Signaling and Circuitry Research Group (SNC), and the Interdisciplinary Research Center on Brain and Learning (CIRCA). He also contributes to the Oncopole, a research, development, and investment hub accelerating cancer fight efforts.

Margaret Alexanderمشاهده پروفایل

استادیار

• Microbiome-Immune Interactions
• Autoimmunity
• Diet-Microbiota-Immune Axis
• +۳ مورد دیگر

Dr. Margaret Alexander is an Assistant Professor in the Department of Medical Microbiology and Immunology at the University of Wisconsin-Madison, where she leads a research laboratory focused on the interactions between diet, the gut microbiota, and the immune system in autoimmune diseases. She began her independent career at UW-Madison in January 2024 after completing postdoctoral training at UCSF. Her educational background includes: B.S. in Biology from Carleton College Ph.D. from the University of Utah under Dr. Ryan O'Connell, studying immune cell communication Postdoctoral work at UCSF with Dr. Peter Turnbaugh on microbiota-immune interactions in autoimmunity Dr. Alexander's research centers on decoding mechanistic interactions between diet, microbiota, and immune responses using mouse models, gnotobiotics, anaerobic microbiology, and sequencing . Her lab investigates how dietary components shape microbial metabolism and immune function, with particular focus on Th17 cell regulation, microbial enzyme activity, and metabolite-mediated host responses in conditions like inflammatory bowel disease and rheumatoid arthritis. This work bridges fundamental microbiology with translational applications for autoimmune disease treatment. Analysis of her recent publications reveals three dominant trends: (1) Identification of specific microbial metabolites (e.g., lactate, polyphenol derivatives) that modulate immune pathways; (2) Development of precision tools for microbiome manipulation including phage-delivered CRISPR; and (3) Investigation of dietary interventions (ketogenic diets, prebiotics) as therapeutic strategies. Her work consistently connects microbial metabolic capabilities to host immune outcomes in autoimmunity. Her scientific contributions have been recognized through prestigious awards: T32 fellowship F32 fellowship K99/R00 career development award Dr. Alexander mentors a diverse research team using a philosophy emphasizing collaboration, creativity, and clear communication . She currently advises two Ph.D. students (Wenxuan Dong and Gillian Hughes) and supervises postdoctoral scholars, with structured mentoring through weekly 1:1 meetings and annual planning sessions. Her lab has secured significant grant funding including NIH K99/R00 support for her diet-microbiome-immune axis research. The Alexander Lab operates within the Microbial Sciences Building at UW-Madison as a dynamic interdisciplinary team comprising postdoctoral scholars, graduate students, a research specialist, and undergraduate researchers. They employ integrated approaches spanning microbial ecology, immunology, and systems biology to unravel complex host-microbe-diet interactions, with ongoing projects focused on microbial enzyme characterization, therapeutic dietary strategies, and microbiome-based biomarkers for autoimmune disease progression.

Oh Jeong-miمشاهده پروفایل

استاد

• Clinical Pharmacy
• Pharmacogenomics
• Translational Research
• +۳ مورد دیگر

Oh Jeong-mi is a Professor in the Department of Pharmacy, College of Pharmacy, Seoul National University, and concurrently holds a Professorship at Seoul National University Hospital since 2005. Her 20-year academic career at SNU progressed from Assistant Professor (2004-2007) to Associate Professor (2007-2012) and full Professor (2012-present), with additional leadership roles including Chairman of the Practical Training Committee for the Korean Council for Pharmaceutical Education (2010-2012). Education: B.S. from University of Texas at Austin Pharm.D. from University of Maryland at Baltimore Professor Oh's research centers on clinical and translational pharmacy with three interconnected pillars: (1) pharmacogenomics of drug transporters and metabolic enzymes in organ transplantation, (2) age- and disease-specific drug safety and appropriateness, and (3) chemotherapy optimization through pharmacokinetic modeling. Her work bridges genomic science with clinical practice to enable personalized immunosuppressant therapy, particularly for kidney and liver transplant recipients. Analysis of her 15 most recent publications reveals dominant research trajectories in CYP3A5/ABCB1 polymorphism impacts on tacrolimus/cyclosporine pharmacokinetics, with strong emphasis on Korean population-specific responses. Key subfields include pharmacometric modeling, transplant immunology, and genetic biomarker validation, consistently targeting clinical implementation of precision dosing protocols. Scientific Awards: Howol Songam Next-Generation Academic Award (2022) She has mentored 11 graduate students in pharmacogenomic applications for transplantation and oncology, with thesis topics spanning population pharmacokinetics, genetic association studies, and multidisciplinary team care models. Her research is conducted through the Clinical Pharmacy Laboratory, which employs collaborative frameworks involving clinicians, geneticists, and pharmacometricians to address complex drug therapy challenges in high-risk patient populations. The laboratory maintains active partnerships with Seoul National University Hospital's transplant and oncology units, focusing on real-world implementation of pharmacogenomic-guided dosing protocols while investigating novel drug-drug interaction mechanisms in polypharmacy scenarios common among elderly and multi-morbid patients.

Bradford G. Orrمشاهده پروفایل

استاد

• Experimental Condensed Matter Physics
• Surface Science
• Nanotechnology
• +۷ مورد دیگر

Bradford G. Orr is the Arthur F. Thurnau Professor of Physics in the College of Literature, Science, and the Arts at the University of Michigan , where he also serves as Associate Vice President for Research (Science & Engineering) . His group uses scanning probe microscopies and molecular-beam epitaxy to explore surface-controlled phenomena in nanoscale semiconductors and, in parallel, engineers multifunctional dendrimer nanoparticles for targeted cancer therapy. Education Ph.D. Physics, University of Minnesota, 1985 B.S. Physics, University of Minnesota, 1980 Research Interests Professor Orr’s work sits at the intersection of condensed-matter physics , surface science , and nanomedicine . He investigates: Surface & Interface Physics: atomically-resolved structures of Si/SiO₂ interfaces, self-assembled monolayers on Au, and composition-modulated compound-semiconductor superlattices. Nanobiotechnology: functional poly(amidoamine) dendrimers as drug-delivery vehicles, lipid-membrane interactions, and real-time AFM imaging of cancer-cell apoptosis. Cross-disciplinary Collaboration: active partnerships with Chemistry, Materials Science, the Medical School, and the Center for Biologic Nanotechnology. Scientific Awards Arthur F. Thurnau Professorship (endowed chair) Grants & Advising While specific grant numbers are not listed, his sustained publication output from 1994 through 2021, coupled with leadership roles in university-wide research administration, indicates continuous federal and institutional funding. The group trains a steady stream of graduate students and postdoctoral researchers, though individual advisee names are not provided in the text. Labs & Facilities Research is conducted in the Randall Lab and Homer A. Neal Lab within the Department of Physics, 450 Church Street, Ann Arbor, MI, and leverages shared instrumentation across the University of Michigan nanofabrication and biological imaging cores.

• Stem Cell Biology
• Neurosurgery
• Brain Tumor Research
• +۵ مورد دیگر

Viviane Tabar, MD, is a neurosurgeon-scientist and Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSKCC). Her clinical expertise focuses on brain tumor surgery, including complex gliomas, meningiomas, and skull base tumors. Her research lab explores stem cells for brain repair and tumor modeling. Key projects include using human pluripotent stem cells to model pediatric gliomas and developing therapies for radiation-induced brain injury. She leads collaborations with the Center for Stem Cell Biology and Brain Tumor Center at SKI. Her lab’s work aims to advance cell-based therapies for Parkinson’s disease and identify novel treatments for brain tumors like diffuse intrinsic pontine glioma (DIPG). Education: MD from the American University of Beirut. Affiliations: Memorial Hospital Research Laboratories, Cancer Biology & Genetics Program, Center for Cell Engineering, Center for Stem Cell Biology, Gerstner Sloan Kettering Graduate School. She also holds leadership roles in translational research initiatives, including NYSTEM consortium grants. Labs/Teams: The Viviane Tabar Lab collaborates with the Allis Lab, Studer Lab, and Soulet Lab. Current projects include drug screening for epigenetic therapies targeting histone mutations in tumors and optimizing stem cell-derived dopamine neurons for clinical trials.

Alisa N. Femiaمشاهده پروفایل

دانشیار

• Autoimmune Connective Tissue Diseases
• Dermatomyositis
• Cutaneous Lupus Erythematosus
• +۴ مورد دیگر

Alisa N. Femia, MD is an Associate Professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine. She serves as Director of Faculty Development and Director of Inpatient Dermatology at NYU Langone. Her clinical expertise focuses on autoimmune cutaneous conditions, including dermatomyositis, cutaneous lupus, and systemic sclerosis. Dr. Femia completed a dermatology-rheumatology fellowship at Brigham and Women’s Hospital (Harvard Medical School), enhancing her capacity to manage complex multisystem autoimmune diseases. She is actively involved in medical education, having received multiple teaching awards, and participates in national medical societies. Her research investigates autoimmune skin disorders, with publications in high-impact journals like Lancet and JAMA Dermatology . She leads clinical trials exploring novel therapies for inflammatory myopathies and has contributed to over 110 publications. Dr. Femia provides care at NYU Langone Dermatologic Associates, emphasizing holistic patient care that integrates medical and dermatologic expertise.

Orhan Ünalمشاهده پروفایل

استاد

• Obstetrics and Gynecology
• Gynecologic Oncology
• Infertility
• +۴ مورد دیگر

Prof. Orhan Ünal is a full Professor at the Faculty of Medicine, Yeditepe University , in the Department of Obstetrics and Gynecology . He has served as Head of Department at Sakarya University in 2014. His clinical and academic work focuses on high-risk pregnancies, gynecologic oncology, infertility, and minimally invasive gynecologic surgery. His research spans a wide range of topics including placental abruption, ectopic pregnancy, chronic gynecologic conditions, and rare ovarian tumors. He has presented extensively at national and international congresses and contributed to case reports and retrospective studies. Research Interests: Obstetric complications such as placental abruption and uterine atony Gynecologic oncology including ovarian carcinoid and leiomyosarcoma Infertility and unexplained infertility diagnostics Urogynecology and stress urinary incontinence Minimally invasive gynecologic surgery Scientific Contributions: Published over 15 peer-reviewed articles and case reports Presented at national and international congresses including the European Congress of Obstetrics and Gynaecology Invited speaker on topics such as urinary incontinence and HSIL management Administrative & Academic Roles: Head of Department, Sakarya University (2014) Faculty member, Yeditepe University Supervisor of clinical and academic training in obstetrics and gynecology

Naomi Winickمشاهده پروفایل

استاد

• Pediatric Oncology
• Hematology
• Leukemia Therapy
• +۵ مورد دیگر

Dr. Naomi Winick is a Professor in the Department of Pediatrics at UT Southwestern Medical Center, specializing in childhood acute lymphoblastic leukemia and neurotoxicity from cancer therapy. She earned her MD from Northwestern University, completed pediatrics residency at Columbia University, and advanced training in pediatric hematology/oncology at Memorial Sloan Kettering and the University of Texas Health Science Center, where she also earned a Master’s in Public Health. Board certified in both general pediatrics and pediatric hematology-oncology, she has been at UT Southwestern since 1985. Her research focuses on leukemia treatment efficacy, genetic factors influencing leukemia susceptibility, and mitigating therapy-related neurotoxicity. She has authored over 200 peer-reviewed articles, contributed to books like Cancer in Children , and serves on key committees including the Children’s Oncology Group Institutional Performance Review Committee and National Cancer Institute’s Pediatric Leukemia and Lymphoma Steering Committee. In 2020, she received the President’s Award for Diversity and Humanism in Clinical Medicine at UT Southwestern. Dr. Winick actively participates in clinical trials through the Children’s Oncology Group, focusing on improving treatment protocols for high-risk leukemias and minimizing side effects. Her work spans genetics, clinical pharmacology, and quality-of-life outcomes in pediatric cancer patients.

• Neuro-Oncology
• Brain Tumors
• Clinical Neurology
• +۴ مورد دیگر

Sylvia Kurz, MD, PhD, is an Associate Professor of Neurology specializing in Neuro-Oncology at Yale School of Medicine. She leads patient care at the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center. Her research focuses on developing novel therapies and optimizing treatment protocols for brain tumors, particularly gliomas and meningiomas. Dr. Kurz holds dual degrees from Ludwig-Maximilians-University in Munich, Germany, and has completed advanced training at institutions including Massachusetts General Hospital and Perlmutter Cancer Center. Roles: Neuro-Oncologist, Associate Professor, Molecular Medicine Researcher Affiliations: Yale School of Medicine, Smilow Cancer Hospital, Chênevert Family Brain Tumor Center Education: MD and PhD: Ludwig-Maximilians-University, Munich Residency: University Hospitals Case Medical Center Fellowship: Massachusetts General Hospital/Dana-Farber Cancer Institute Dr. Kurz’s research emphasizes translational neuro-oncology, including radiopharmaceuticals, targeted therapies, and biomarker-guided treatment strategies. Her clinical work integrates cutting-edge diagnostics like SSTR2 PET imaging and molecular methylation profiling. She has pioneered initiatives like the DivINe Initiative to promote diversity in neuro-oncology leadership and co-developed the NEURO-MCBS clinical benefit scale for CNS tumor trials. Her clinical trials focus on therapies for glioblastoma, meningioma, and diffuse midline glioma (DMG), including ONC201 for H3 K27M-mutant tumors and LITT for glioblastoma recurrence. She also addresses care challenges such as venous thromboembolism management in brain tumor patients and caregiver psychosocial burdens. Dr. Kurz collaborates extensively with teams at Yale Cancer Center, the Molecular Tumor Board (TRACE initiative), and international neuro-oncology groups like NCOG. Her work spans from bench-to-bedside innovations in immunotherapy and precision medicine to improving patient-reported outcomes through digital health tools.